Difference between revisions of "Ublituximab (Briumvi)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670500 NCI Drug Dictionary]: A chimeric recombinant IgG1 monoclonal antibody...") |
m |
||
| (23 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670500 NCI Drug Dictionary]: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670500 NCI Drug Dictionary]: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells. | ||
| − | = | + | ==Diseases for which it is used== |
| − | ==[[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)|CLL] | + | *[[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)|CLL]] |
| − | |||
| − | =Also known as= | + | ==History of changes in FDA indication== |
| − | LFB-R603, TG-20, TGTX-1101 | + | ''No antineoplastic indication, at this time.'' |
| + | *2023-01-06: Approved for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. | ||
| + | ==Also known as== | ||
| + | *'''Code names:''' LFB-R603, TG-20, TG-1101, TGTX-1101 | ||
| + | *'''Generic name:''' ublituximab-xiiy | ||
| + | *'''Brand name:''' Briumvi | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | + | [[Category:Intravenous medications]] | |
| − | [[Category:Intravenous | ||
| − | |||
| − | |||
[[Category:Anti-CD20 antibodies]] | [[Category:Anti-CD20 antibodies]] | ||
| − | [[Category:Chronic lymphocytic leukemia | + | [[Category:Chronic lymphocytic leukemia medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2023]] |
Latest revision as of 01:28, 13 January 2024
Mechanism of action
From the NCI Drug Dictionary: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.
Diseases for which it is used
History of changes in FDA indication
No antineoplastic indication, at this time.
- 2023-01-06: Approved for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Also known as
- Code names: LFB-R603, TG-20, TG-1101, TGTX-1101
- Generic name: ublituximab-xiiy
- Brand name: Briumvi